Earnings OutTop line comparables are a little weaker than 2009, but overall, first half revenues are up12%. Expenses are coming down however and the share buy back is resulting in an expansion of earnings per share.
All and all not bad and two new products coming on stream in the second half.
Suprprising collision of shares I own. Sara Elford, who sits on the Biosyent board has been named to the Xebec board (V.XBC) smalll world
overnout